Graft-versus-host disease: The viewpoint from the donor T cell

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 1, 1997, Pages 1-10

  Chao, Nelson J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Box 3961 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(T,G) A L; (T,G)-A-L; CELL ADHESION MOLECULE; CYTOKINE; HISTOCOMPATIBILITY ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; SUPERANTIGEN;

ANIMAL; ANTIGEN PRESENTATION; CELL ADHESION; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; PATHOLOGY; PHYSIOLOGY; REVIEW; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION;

ANIMALS; ANTIGEN PRESENTATION; CELL ADHESION; CELL ADHESION MOLECULES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MICE; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; SUPERANTIGENS; T-LYMPHOCYTE SUBSETS;

EID: 0031115135     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Billingham R: The biology of graft-versus-host reaction. Harvey Lecture: 21, 1966.
2. Palathumpat V, Dejbakhsh-Jones S, Holm B, Strober S: Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol 149:808, 1992.
3. Strober S, Hertel-Wuff B, Schwadron RB: Role of natural suppressor cells in bone marrow transplantation. Transplant Proc 6:88, 1987.
4. Antin J, Bierer B, Smith BR, Ferrara J, Guinan EC, Seiff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E, Reichert TA, Blythman H, Boloux C, Rappeport Jm, Burakoff Sj, Weinstein HJ: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139, 1991.
5. + T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 15:418, 1990.
6. Goldman J, Gale RP, Horowitz M, Biggs JC, Champlin RE, Gluckman E, Hoffman RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner R, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T cell depletion. Ann Intern Med 108:806, 1988.
7. Hale G, Cobbold SP, Waldman H: For Campath-1 Users. T-cell depletion with Campath-1 in allogeneic bone marrow transplantation. Transplantation 45:753, 1988.
8. Martin P, Hansen JA, Buckner CD, Sanders JE, Deeg J, Stewart P, Appelbaum F, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Flournoy N, Storb R, Thomas ED: Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66:664, 1985.
9. Soiffer R, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Robertson MJ, Spector N, Gorin R, Miller KB, Rudders RA, Freeman A, Blake K, Coral F, Nadler LM, Ritz J: Prevention of graft-versus-host disease by selective depletion of CD6 positive T lymphocytes from donor bone marrow. J Clin Oncol 11:1191, 1992.
10. Kernan NA, Cliins NH, Juliana L, Cartagena T, Dupont B, O'Reilly RJ: Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68:770, 1986.
11. Potter M, Pamphilon DH, Cornish JM, Oakbill A: Graft-versus-host disease in children receiving HLA-identical allogeneic bone marrow transplants with a low adjusted T lymphocyte dose. Bone Marrow Transpl 8:357, 1991.
12. Aversa G, Waugh JA, Hall BM: A monoclonal antibody (A6) recognizing a unique epitope restricted to CD45RO and RB isoforms of the leukocyte common antigen family identifies functional T cell subsets. Cellular Immunology 158:314, 1994.
13. + lymphocytes. Eur J Immunol 25:644, 1995.
14. + T cells following immunization. Eur J Immunol 25:1755, 1995.
15. Lazarovits A, Poppema S, Zhang Z, Khandaker M, Le Feuvre CE, Singhal SK, Garcia BM, Ogasa N, Jevnikar AM, White MH, Singh G, Stitter CR, Zhong RR: Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 380:717, 1996.
16. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Eng J Med 335:157, 1996.
17. Dejbakhsh-Jone, S, Jerabek L, Weissman IL, Strober S: Extrathymic maturation of alpha beta T cells from hemopoietic stem cells. J Immunol 155:3338, 1995.
18. Cheng L, Dejbakhsh-Jones S, Liblau R, Zeng D, Strober S: Different patterns of TCR transgene expression in single-positive and double-negative T cells. Evidence for separate pathways of T cell maturation. J Immunol 156:3591, 1996.
19. Udaka K, Wiesmuller K-H, Kienle S, Jung G, Walden P: Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J Immunol 157:670, 1996.
20. Schlegel PG, Aharoni R, Smilek DE, Fernandez LP, McDevitt HO, Tran N, Vaysburd M, Chao NJ: Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 84:2802, 1994.
21. del Guercio M-F, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A: Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 154:685, 1995.
22. Schlegel, PG, Aharoni R, Chen Y, Chen J, Teitelbaum D, Arnon R, Sela M, Chao NJ: A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Nat Acad Sci (USA) 93:5061, 1996.
23. Jameson B, McDonnell JM, Marini JC, Korngold R: A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 368:744, 1994.
24. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, Grathwohl A, Vogelsang GB, van Houwelingen HC, van Rood JJ: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334:281, 1996.
25. de Haan J, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268:1476, 1995.
26. Sloan-Lancaster J, Allen PM: Significance of T-cell stimulation by altered peptide ligands in T cell biology. Cur Op Immunol 7:103, 1995.
27. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K: Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 181:1569, 1995.
28. Vidal K, Hsu BL, Williams CB, Allen PM: Endogenous altered peptide ligands can affect peripheral T cell responses. J Exp Med 183:1311, 1996.
29. Zehnder J, Hirai K, Shatsky M, McGregor JL, Levitt LJ, Leung LL: The cell adhesion molecule CD31 is phosphorylated after cell activation. Down-regulation of CD31 in activated T lymphocytes. J Biol Chem 267:5243, 1992.
30. Stockinger H, Schreiber W, Majdic O, Holter W, Maurer D, Knapp W: Phenotype of human T cells expressing CD31, a molecule of the immunoglobulin supergene family. Immunol 75:53, 1992.
31. Simmons D, Walker C, Power C, Pigott R: Molecular cloning of CD31, a putative intercellular adhesion molecule closely related to carcinoembryonic antigen. J Exp Med 171:214, 1990.
32. Newman P, Berndt BM, Gorski J, White GC, Lyman S, Paddock C, Muller WA: PECAM (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247:1219-1221, 1990.
33. Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D, Imhof BA: CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol 130:451, 1995.
34. Prager E, Sunder-Plassmann R, Hansmann C, Koch C, Holter W, Knapp W, Stockinger H: Interaction of CD31 with a heterophilic counterreceptor involved in downregulation of human T cell responses. J Exp Med 184:41, 1996.
35. Behar E, Chao NJ, Hiraki DD, Krishnaswamy S, Brown BW, Zehnder JL, Grumet FC: Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 334:286, 1996.
36. Nichols W, Antin JH, Lunetta KL, Terry VH, Hertel CE, Wheatley MA, Arnold ND, Siemieniak DR, Boehnke M, Ginsburg D: Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood, in press.
37. Maruya E, Yokohama S, Saji H: Polymorphisms of the cell adhesion molecule CD31 in Japanese and association with graft-versus-host disease after allogeneic bone marrow transplantation. Human Immunol 49 (suppl 1):3, 1996.
38. Matsui K, Boniface JJ, Steffner P, Reay PA, Davis MM: Kinetics of T-cell receptor binding to peptide/I-Ek complexes: Correlation of the dissociation rate with T-cell responsiveness. Proc Nat Acad Sci (USA) 91:12862, 1994.
39. Butcher E, Picker LJ: Lymphocyte homing and homeostasis. Science 272:60, 1996.
40. Sette A, Alexander J, Grey HM: Interaction of antigenic peptides with MHC and TCR molecules. Clin Immunol Immunopath 76:168-71, 1995.
41. Sakihama T, Smolyar A, Reinherz EL: Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Immunol Today 16:581, 1995.
42. Yang Y, Wilson JM: CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40. Science 273:1862, 1996.
43. June C, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 15:321, 1994.
44. Green J, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB: Absence of B7-dependent responses in CD28-deficient mice. Immunity 1:501, 1994.
45. Freeman G, Gribben JG, Boussiotis VA, Restino VA, Lombard LA, Gray GS, Nadler LM: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 209:909, 1993.
46. Boussiotis V, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM: Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 184:365, 1996.
47. Wallace P, Johnson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS: CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplant 58:602, 1994.
48. Schlegel P, Vaysburg M, Chen Y, Butcher EC, Chao NJ: Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. J Immunol 155:3856, 1995.
49. Durie F, Foy TM, Masters SR, Laman JD, Noelle RJ: The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 15:406, 1994.
50. Grewal I, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA, Jr: Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273:1864, 1996.
51. Jadus M, Wepsic HT: The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transpl 10:1, 1992.
52. Korngold R, Sprent J: T cell subsets and graft-versus-host disease. Transplant 44:335-339, 1987.
53. Mason D: Subsets of T cells in the rat mediating lethal graft versus host disease. Transplant 32:222, 1981.
54. + T cell clones secrete the Th1 pattern of cytokines. J Immunol 144:1744, 1990.
55. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16:34, 1995.
56. + T cells. Immunol Today 12: 392, 1991.
57. Mosmann T, Moore KE: The role of IL10 in crossregulation of Th1 and Th2 responses. Immunol Today 12:A49, 1991.
58. Street N, Mosmann TR: Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 5:171, 1991.
59. + T cells. J Immunol 155:2396, 1995.
60. Fowler D, Kurasawa K, Smith R, Eckhaus MA, Gress RE: Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540, 1994.
61. + T cells. J Exp Med 184:19, 1996.
62. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL: Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422, 1995.
63. Sykes M, Szot GL, Nguyen PL, Pearson DA: Interleukin-12 inhibits murine graft-versus-host disease. Blood 86:2429, 1995.
64. Broxmeyer H, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS, Hoffman R, Rubin BY: The suppressive influences of human tumor necrosis factor on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon-gamma. J Immunol 136:4487, 1986.
65. + helper cells. Transplant 60:481, 1995.
66. Sykes M, Abraham FS: The mechanism of IL-2-mediated protection against GVHD in mice. Transplant 53:1063-1070, 1992.
67. Sykes M: Dissociating graft-vs-host disease from the graft-vs-leukemia effect of allogeneic T cells: The potential role of IL-2. Bone Marrow Transpl 10 Suppl:1, 1992.
68. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rhum IJ, Falzarano G, Bloedow DC, Abate L, Lebsack M, Burakoff SJ, Ferrara LM: Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84:1342, 1994.
69. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, Doney K, Hansen JA, Mason M, Sanders JE, Singer J, Sullivan KM, Witherspoon RP, Thomas ED: Graft versus host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective enviroment. New Engl J Med 308:302, 1983.
70. Moore R, Lampert IA, Chia Y, Aber VR, Cohen J: Effect of immunisation with Escherichia coli J5 in graft versus host disease induced by minor histocompatibility antigens in mice. Transplant 44:249, 1987.
71. Piguet P, Grau GE, Allet B, Vassalli P: Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 166:1280, 1987.
72. Shalaby M, Fendly B, Sheehan K, Schreiber RD, Ammann AJ: Prevention of the graft versus host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplant 47:1057, 1989.
73. Holler E, Kolb HJ, Möller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher N, Ruckdeschel G, Leixner B, Riedner C, Ledderose G, Buhm G, Mittermüller J, Wilmanns W: Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 75:1011, 1990.
74. Miconnet I, Roger T, Seman M, Bruley-Rosset M: Critical role of endogenous Mtv in acute lethal graft-versus-host disease. Eur J Immunol 25:364, 1995.
75. Sutkowski N, Palkama T, Xu L, Huber B: Characterization of T cell stimulatory elements in Epstein Barr virus (EBV): Role of a potential superantigen. The Ninth International Congress of Immunology:717 (4257), 1995.
76. Baker M, Podack ER, Levy RB: Fas and perform cytotoxic pathways are not the major effector mechanisms in allogeneic resistance to bone marrow. Ann New York Acad Sci 770:368, 1995.
77. Baker M, Altman NH, Podack ER, Levy RB: The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645, 1996.
78. Griffith T, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189, 1995.
79. Chen J, Morris RE, Chao NJ: Effective prevention of murine graft-versus-host disease by rapamycin is associated with the appearance of suppressor cells. Blood 88 (Suppl 1):982, 1996.
80. Morecki S, Leshem B, Weigensberg M, Bar S, Slavin S: Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation. Transplantation 40:201, 1985.
81. Strober S, Palathumpat V, Schwadron R, Hertel-Wulff B: Cloned natural suppressor cells prevent lethal graft-vs-host disease. J. Immunol. 138:699, 1987.
82. + cells. J. Immunol. 145:3209, 1990.